Astellas Pharma's gastric cancer therapy has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This approval is a significant step forward for the treatment of patients with advanced or metastatic gastric cancer, offering a new option for those who may have exhausted other therapies. The approval also highlights the ongoing efforts to provide innovative treatments in oncology, particularly in areas with high unmet needs.